Efficacy and updated safety results from pivotal phase II trial 201 of naxitamab (Hu3F8): A humanized GD2-targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB) Meeting Abstract
| Authors: | Mora, J.; Chan, G. C.; Morgenstern, D. A.; Nysom, K.; Bear, M.; Worsaae Dalby, L.; Lisby, S.; Kushner, B. H. |
| Abstract Title: | Efficacy and updated safety results from pivotal phase II trial 201 of naxitamab (Hu3F8): A humanized GD2-targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB) |
| Meeting Title: | ESMO Immuno-Oncology Virtual Congress 2020 |
| Journal Title: | Annals of Oncology |
| Volume: | 31 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2020 Dec 9-12 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2020-12-01 |
| Start Page: | S1448 |
| Language: | English |
| ACCESSION: | WOS:000600992500076 |
| DOI: | 10.1016/j.annonc.2020.10.563 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 75P -- Source: Wos |
